nodes	percent_of_prediction	percent_of_DWPC	metapath
Hexobarbital—CYP1A2—Clobetasol propionate—psoriasis	0.187	0.187	CbGbCtD
Hexobarbital—CYP1A2—Methoxsalen—psoriasis	0.098	0.0984	CbGbCtD
Hexobarbital—CYP2C19—Cholecalciferol—psoriasis	0.0704	0.0706	CbGbCtD
Hexobarbital—CYP3A4—Calcitriol—psoriasis	0.066	0.0663	CbGbCtD
Hexobarbital—CYP2C9—Cholecalciferol—psoriasis	0.0585	0.0587	CbGbCtD
Hexobarbital—CYP3A4—Methoxsalen—psoriasis	0.0514	0.0516	CbGbCtD
Hexobarbital—CYP2C19—Prednisone—psoriasis	0.0488	0.049	CbGbCtD
Hexobarbital—CYP2E1—Dexamethasone—psoriasis	0.0486	0.0488	CbGbCtD
Hexobarbital—CYP2C19—Cyclosporine—psoriasis	0.0462	0.0464	CbGbCtD
Hexobarbital—CYP2C9—Cyclosporine—psoriasis	0.0384	0.0386	CbGbCtD
Hexobarbital—CYP3A4—Cholecalciferol—psoriasis	0.034	0.0341	CbGbCtD
Hexobarbital—CYP2C19—Dexamethasone—psoriasis	0.0305	0.0306	CbGbCtD
Hexobarbital—CYP3A4—Mycophenolate mofetil—psoriasis	0.0295	0.0296	CbGbCtD
Hexobarbital—CYP3A4—Triamcinolone—psoriasis	0.0295	0.0296	CbGbCtD
Hexobarbital—CYP2C9—Dexamethasone—psoriasis	0.0253	0.0254	CbGbCtD
Hexobarbital—CYP3A4—Betamethasone—psoriasis	0.0253	0.0254	CbGbCtD
Hexobarbital—CYP3A4—Prednisolone—psoriasis	0.025	0.0251	CbGbCtD
Hexobarbital—CYP3A4—Hydrocortisone—psoriasis	0.0237	0.0238	CbGbCtD
Hexobarbital—CYP3A4—Prednisone—psoriasis	0.0236	0.0237	CbGbCtD
Hexobarbital—CYP3A4—Cyclosporine—psoriasis	0.0224	0.0224	CbGbCtD
Hexobarbital—CYP3A4—Dexamethasone—psoriasis	0.0147	0.0148	CbGbCtD
Hexobarbital—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.000262	0.0694	CbGpPWpGaD
Hexobarbital—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000202	0.0536	CbGpPWpGaD
Hexobarbital—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000184	0.0488	CbGpPWpGaD
Hexobarbital—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.000162	0.043	CbGpPWpGaD
Hexobarbital—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000125	0.0332	CbGpPWpGaD
Hexobarbital—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000114	0.0303	CbGpPWpGaD
Hexobarbital—CYP1A2—Xenobiotics—CYP2S1—psoriasis	9.76e-05	0.0259	CbGpPWpGaD
Hexobarbital—CYP3A4—Xenobiotics—CYP2S1—psoriasis	7.54e-05	0.02	CbGpPWpGaD
Hexobarbital—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.32e-05	0.0194	CbGpPWpGaD
Hexobarbital—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	6.74e-05	0.0179	CbGpPWpGaD
Hexobarbital—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	6.66e-05	0.0176	CbGpPWpGaD
Hexobarbital—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.47e-05	0.0145	CbGpPWpGaD
Hexobarbital—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	5.4e-05	0.0143	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—RUNX3—psoriasis	5.37e-05	0.0142	CbGpPWpGaD
Hexobarbital—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	5.2e-05	0.0138	CbGpPWpGaD
Hexobarbital—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	5.14e-05	0.0136	CbGpPWpGaD
Hexobarbital—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.74e-05	0.0126	CbGpPWpGaD
Hexobarbital—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4.68e-05	0.0124	CbGpPWpGaD
Hexobarbital—GABRA6—Orphan transporters—CARM1—psoriasis	4.41e-05	0.0117	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—RUNX3—psoriasis	4.37e-05	0.0116	CbGpPWpGaD
Hexobarbital—GABRA4—Orphan transporters—CARM1—psoriasis	4.36e-05	0.0115	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—IL13—psoriasis	4.24e-05	0.0112	CbGpPWpGaD
Hexobarbital—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	4.22e-05	0.0112	CbGpPWpGaD
Hexobarbital—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.05e-05	0.0107	CbGpPWpGaD
Hexobarbital—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4e-05	0.0106	CbGpPWpGaD
Hexobarbital—PTGS1—Biological oxidations—CYP2S1—psoriasis	3.89e-05	0.0103	CbGpPWpGaD
Hexobarbital—GABRA5—Orphan transporters—CARM1—psoriasis	3.87e-05	0.0103	CbGpPWpGaD
Hexobarbital—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	3.85e-05	0.0102	CbGpPWpGaD
Hexobarbital—GABRA3—Orphan transporters—CARM1—psoriasis	3.8e-05	0.0101	CbGpPWpGaD
Hexobarbital—GABRA2—Orphan transporters—CARM1—psoriasis	3.74e-05	0.00989	CbGpPWpGaD
Hexobarbital—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	3.51e-05	0.00931	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—IL13—psoriasis	3.45e-05	0.00915	CbGpPWpGaD
Hexobarbital—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	3.29e-05	0.00871	CbGpPWpGaD
Hexobarbital—GABRA1—Orphan transporters—CARM1—psoriasis	3.18e-05	0.00844	CbGpPWpGaD
Hexobarbital—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	3.13e-05	0.00829	CbGpPWpGaD
Hexobarbital—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.1e-05	0.00821	CbGpPWpGaD
Hexobarbital—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	3.09e-05	0.00818	CbGpPWpGaD
Hexobarbital—CYP2E1—Biological oxidations—CYP2S1—psoriasis	2.9e-05	0.00769	CbGpPWpGaD
Hexobarbital—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	2.86e-05	0.00759	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—RUNX3—psoriasis	2.71e-05	0.00717	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—IL10—psoriasis	2.65e-05	0.00702	CbGpPWpGaD
Hexobarbital—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	2.54e-05	0.00672	CbGpPWpGaD
Hexobarbital—CYP2E1—Tryptophan metabolism—CAT—psoriasis	2.51e-05	0.00664	CbGpPWpGaD
Hexobarbital—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	2.5e-05	0.00663	CbGpPWpGaD
Hexobarbital—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	2.44e-05	0.00648	CbGpPWpGaD
Hexobarbital—CYP2C19—Biological oxidations—CYP2S1—psoriasis	2.24e-05	0.00594	CbGpPWpGaD
Hexobarbital—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	2.21e-05	0.00586	CbGpPWpGaD
Hexobarbital—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.18e-05	0.00577	CbGpPWpGaD
Hexobarbital—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	2.17e-05	0.00576	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—IL10—psoriasis	2.16e-05	0.00572	CbGpPWpGaD
Hexobarbital—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.16e-05	0.00572	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—IL13—psoriasis	2.14e-05	0.00566	CbGpPWpGaD
Hexobarbital—CYP2C9—Biological oxidations—CYP2S1—psoriasis	2.04e-05	0.00541	CbGpPWpGaD
Hexobarbital—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	2.02e-05	0.00534	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	2e-05	0.00529	CbGpPWpGaD
Hexobarbital—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	1.99e-05	0.00526	CbGpPWpGaD
Hexobarbital—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	1.97e-05	0.00523	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	1.95e-05	0.00515	CbGpPWpGaD
Hexobarbital—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.86e-05	0.00493	CbGpPWpGaD
Hexobarbital—GRIA2—BDNF signaling pathway—NFKBIA—psoriasis	1.82e-05	0.00482	CbGpPWpGaD
Hexobarbital—CYP1A2—Biological oxidations—CYP2S1—psoriasis	1.75e-05	0.00463	CbGpPWpGaD
Hexobarbital—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	1.72e-05	0.00456	CbGpPWpGaD
Hexobarbital—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	1.72e-05	0.00455	CbGpPWpGaD
Hexobarbital—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	1.69e-05	0.00449	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	1.58e-05	0.0042	CbGpPWpGaD
Hexobarbital—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.52e-05	0.00403	CbGpPWpGaD
Hexobarbital—CYP1A2—Tryptophan metabolism—CAT—psoriasis	1.51e-05	0.00399	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	1.46e-05	0.00386	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—CXCL8—psoriasis	1.45e-05	0.00384	CbGpPWpGaD
Hexobarbital—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.44e-05	0.00381	CbGpPWpGaD
Hexobarbital—CYP3A4—Biological oxidations—CYP2S1—psoriasis	1.35e-05	0.00357	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—JUN—psoriasis	1.35e-05	0.00357	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—IL10—psoriasis	1.34e-05	0.00354	CbGpPWpGaD
Hexobarbital—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	1.33e-05	0.00352	CbGpPWpGaD
Hexobarbital—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.3e-05	0.00344	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.3e-05	0.00344	CbGpPWpGaD
Hexobarbital—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	1.29e-05	0.00342	CbGpPWpGaD
Hexobarbital—GRIA2—BDNF signaling pathway—JUN—psoriasis	1.21e-05	0.0032	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—CXCL8—psoriasis	1.18e-05	0.00313	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.18e-05	0.00312	CbGpPWpGaD
Hexobarbital—CYP3A4—Tryptophan metabolism—CAT—psoriasis	1.16e-05	0.00308	CbGpPWpGaD
Hexobarbital—GRIA2—BDNF signaling pathway—NFKB1—psoriasis	1.16e-05	0.00308	CbGpPWpGaD
Hexobarbital—GABRA6—Transmembrane transport of small molecules—CP—psoriasis	1.13e-05	0.00299	CbGpPWpGaD
Hexobarbital—GABRA4—Transmembrane transport of small molecules—CP—psoriasis	1.11e-05	0.00295	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	1.11e-05	0.00294	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—JUN—psoriasis	1.1e-05	0.00291	CbGpPWpGaD
Hexobarbital—GABRA6—Transmembrane transport of small molecules—CARM1—psoriasis	1.08e-05	0.00285	CbGpPWpGaD
Hexobarbital—GABRA4—Transmembrane transport of small molecules—CARM1—psoriasis	1.06e-05	0.00282	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.06e-05	0.0028	CbGpPWpGaD
Hexobarbital—GRIA2—BDNF signaling pathway—STAT3—psoriasis	1.04e-05	0.00277	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—TNF—psoriasis	1.01e-05	0.00267	CbGpPWpGaD
Hexobarbital—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	1.01e-05	0.00267	CbGpPWpGaD
Hexobarbital—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1e-05	0.00265	CbGpPWpGaD
Hexobarbital—GABRA5—Transmembrane transport of small molecules—CP—psoriasis	9.9e-06	0.00262	CbGpPWpGaD
Hexobarbital—GABRA3—Transmembrane transport of small molecules—CP—psoriasis	9.73e-06	0.00258	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—VEGFA—psoriasis	9.59e-06	0.00254	CbGpPWpGaD
Hexobarbital—GABRA2—Transmembrane transport of small molecules—CP—psoriasis	9.56e-06	0.00253	CbGpPWpGaD
Hexobarbital—GABRA5—Transmembrane transport of small molecules—CARM1—psoriasis	9.45e-06	0.0025	CbGpPWpGaD
Hexobarbital—GABRA3—Transmembrane transport of small molecules—CARM1—psoriasis	9.28e-06	0.00246	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	9.22e-06	0.00244	CbGpPWpGaD
Hexobarbital—GABRA2—Transmembrane transport of small molecules—CARM1—psoriasis	9.12e-06	0.00242	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.37e-06	0.00222	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—TNF—psoriasis	8.22e-06	0.00218	CbGpPWpGaD
Hexobarbital—GABRA1—Transmembrane transport of small molecules—CP—psoriasis	8.15e-06	0.00216	CbGpPWpGaD
Hexobarbital—CHRNA7—SIDS Susceptibility Pathways—IL6—psoriasis	8.14e-06	0.00216	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—NDUFA5—psoriasis	7.82e-06	0.00207	CbGpPWpGaD
Hexobarbital—GABRA1—Transmembrane transport of small molecules—CARM1—psoriasis	7.78e-06	0.00206	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.31e-06	0.00194	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.29e-06	0.00193	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.23e-06	0.00192	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	7.17e-06	0.0019	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.96e-06	0.00184	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—JUN—psoriasis	6.8e-06	0.0018	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—CYP2S1—psoriasis	6.65e-06	0.00176	CbGpPWpGaD
Hexobarbital—CHRNA4—SIDS Susceptibility Pathways—IL6—psoriasis	6.64e-06	0.00176	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.54e-06	0.00173	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.32e-06	0.00167	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.94e-06	0.00157	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—NDUFA5—psoriasis	5.84e-06	0.00155	CbGpPWpGaD
Hexobarbital—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.79e-06	0.00153	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.41e-06	0.00143	CbGpPWpGaD
Hexobarbital—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.41e-06	0.00143	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—TNF—psoriasis	5.09e-06	0.00135	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—CYP2S1—psoriasis	4.97e-06	0.00132	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—NDUFA5—psoriasis	4.51e-06	0.00119	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.2e-06	0.00111	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—NDUFA5—psoriasis	4.11e-06	0.00109	CbGpPWpGaD
Hexobarbital—GABRA1—SIDS Susceptibility Pathways—IL6—psoriasis	4.11e-06	0.00109	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—CYP2S1—psoriasis	3.83e-06	0.00102	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.83e-06	0.00102	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—NDUFA5—psoriasis	3.51e-06	0.00093	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—CYP2S1—psoriasis	3.49e-06	0.000926	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.48e-06	0.000923	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.27e-06	0.000867	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—CARM1—psoriasis	3.25e-06	0.00086	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.03e-06	0.000804	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—CYP2S1—psoriasis	2.99e-06	0.000791	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—NDUFA5—psoriasis	2.71e-06	0.000718	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—CARM1—psoriasis	2.43e-06	0.000643	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—CYP2S1—psoriasis	2.3e-06	0.000611	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.01e-06	0.000532	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—CAT—psoriasis	2e-06	0.000529	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—CARM1—psoriasis	1.87e-06	0.000496	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.83e-06	0.000485	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.75e-06	0.000463	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—CARM1—psoriasis	1.71e-06	0.000452	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.6e-06	0.000423	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.56e-06	0.000415	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—APOE—psoriasis	1.55e-06	0.000411	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—CAT—psoriasis	1.49e-06	0.000395	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—CARM1—psoriasis	1.46e-06	0.000386	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.36e-06	0.000361	CbGpPWpGaD
Hexobarbital—PTGS1—Metabolism—PPARG—psoriasis	1.35e-06	0.000358	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—APOE—psoriasis	1.16e-06	0.000307	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—CAT—psoriasis	1.15e-06	0.000305	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—CARM1—psoriasis	1.13e-06	0.000298	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—CAT—psoriasis	1.05e-06	0.000278	CbGpPWpGaD
Hexobarbital—CYP2E1—Metabolism—PPARG—psoriasis	1.01e-06	0.000268	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—CAT—psoriasis	8.97e-07	0.000238	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—APOE—psoriasis	8.94e-07	0.000237	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—APOE—psoriasis	8.16e-07	0.000216	CbGpPWpGaD
Hexobarbital—CYP2C19—Metabolism—PPARG—psoriasis	7.79e-07	0.000206	CbGpPWpGaD
Hexobarbital—CYP2C9—Metabolism—PPARG—psoriasis	7.1e-07	0.000188	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—APOE—psoriasis	6.97e-07	0.000185	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—CAT—psoriasis	6.92e-07	0.000183	CbGpPWpGaD
Hexobarbital—CYP1A2—Metabolism—PPARG—psoriasis	6.07e-07	0.000161	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—APOE—psoriasis	5.38e-07	0.000142	CbGpPWpGaD
Hexobarbital—CYP3A4—Metabolism—PPARG—psoriasis	4.68e-07	0.000124	CbGpPWpGaD
